Arsenic and 17-β-estradiol bind to each other and neutralize each other's signaling effects

Area of Science:

• Endocrinology
• Molecular Biology
• Environmental Health

Background:

• 17-beta-estradiol (E2) is a key hormone regulating cell survival and proliferation, particularly in breast cancer.
• Arsenic trioxide (ATO) is an environmental toxicant with known cellular effects.
• The interaction between E2 and ATO in breast cancer cells is not well understood.

Purpose of the Study:

• To investigate the interaction between arsenic trioxide (ATO) and 17-beta-estradiol (E2) in breast cancer cells (MCF-7).
• To determine if ATO binding affects E2's signaling pathways.
• To explore potential mechanisms linking arsenic exposure to reproductive and cancer health outcomes.

Main Methods:

• Utilized difference absorption spectroscopy, chromatography-coupled voltammetry, and 1D NMR (¹H and ¹³C) to detect ATO-E2 binding.
• Assessed the impact of ATO on E2-mediated cell survival and proliferation/migration in MCF-7 cells.
• Analyzed spectral changes in E2 upon ATO interaction.

Main Results:

• Arsenic trioxide (ATO) and 17-beta-estradiol (E2) were found to abolish each other's independent effects on breast cancer cell survival and migration.
• Spectroscopic and NMR analyses confirmed direct binding of ATO to E2.
• Binding resulted in the attenuation of specific hydroxyl peaks in E2's NMR spectrum, indicating structural changes.

Conclusions:

• ATO directly binds to E2, altering its molecular structure and attenuating its signaling capabilities.
• This interaction suggests a mechanism by which ATO can interfere with estrogenic pathways.
• The findings may provide insights into the epidemiological observations linking arsenic exposure to altered reproductive health and cancer risk.